Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base
Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-yearExceeding monthly...
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias...
Retail Footprint to Include 12 Open Locations, with 15 Additional Clinics in Development, Ensures Accessibility to Millions with Affordable Treatments and Insurance Coverage
National Presence Will Bring...
TORONTO, September 22, 2021--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) ("Greenbrook" or the "Company"), a leading provider of Transcranial Magnetic Stimulation ("TMS") therapy in the United States, is pleased...
Every successful drug was once in Phase I.
"In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the...
The AdvisorShares Psychedelics ETF (NYSE ticker: PSIL) invests in the emerging psychedelic drugs sector, offering exposure to those biotechnology, pharmaceutical and life sciences companies we see as leading the way in this...
